AD109 efficacy and safety
6 evidence topics · 31 sources
Summary: SynAIRgy phase 3 efficacy
SynAIRgy (APC-APN-305; NCT05813275) was a phase 3, randomized, double-blind, placebo-controlled, 6-month parallel-arm trial at 69 sites in the United States and Canada in adults with mild to severe OSA who had failed or refused PAP therapy. Between December 20, 2023 and March 26, 2025, 646 participants were randomized to AD109 (n = 324) or placebo (n = 322). AD109 was aroxybutynin 2.5 mg (as the hydrochloride; 2.3 mg base) with atomoxetine 37.5 mg for week 1 and atomoxetine 75 mg thereafter, without dose reduction. The primary endpoint was the change in AHI4 (hypopneas with at least 4% desaturation) from baseline to week 26. The treatment policy (intent-to-treat) set included 615 participants (302 and 313) and the on-treatment estimand 556 (260 and 296); median baseline AHI in the treatment policy set was 19.6.
- Primary endpoint, treatment policy estimand: least-squares mean change of −3.3 with AD109 and 0.7 with placebo, a difference of −4.0 events/h (95% CI −6.4 to −1.6; P = .001), corresponding to a model-estimated geometric mean reduction of 44.1% against 17.6%. Median AHI fell from 19.8 to 13.3 with AD109 and from 19.1 to 17.7 with placebo.
- Primary endpoint, on-treatment estimand: −6.1 against 0.4, a difference of −6.5 events/h (95% CI −8.8 to −4.3; P <.0001), or 55.6% against 19.1%. The company topline release reported the primary endpoint P value (0.001) together with the 55.6% reduction, which is the on-treatment figure.
- Key secondary endpoints, treatment policy estimand, in testing order: oxygen desaturation index (3%) difference −4.5 (P = .001); PROMIS-Fatigue T-score difference −1.2 (P = .059), after which formal hierarchical testing ended; hypoxic burden reduction 44.7% against 8.5% (nominal P <.0001); PROMIS-Sleep Impairment difference −0.7 (P = .316); at least 50% AHI reduction in 25.8% against 19.8% (difference 5.7; 95% CI −1.0 to 12.4; P = .182), with participants who discontinued treatment counted as nonresponders.
- On-treatment estimand: at least 50% AHI reduction in 39.6% against 22.3% (P <.0001) and PROMIS-Fatigue difference −1.4 (P = .030).
- Disease control (AHI below 5) at week 26 occurred in 17.6% with AD109 against 9.3% with placebo under the treatment policy estimand (P = .012); the company reports 22.3% with AD109 under the on-treatment estimand.
- An accompanying editorial described the placebo-adjusted reduction as approximately 4 events per hour and stated that the clinical significance of this magnitude is uncertain as a continuous measure.
Summary: LunAIRo phase 3 efficacy
LunAIRo (APC-APN-304; NCT05811247) was a randomized, double-blind, placebo-controlled, 1-year parallel-arm trial at 64 U.S. sites in adults with mild to severe OSA who were intolerant of, or refused, PAP. LunAIRo has no full publication; its results come from a congress abstract, the registry record, and company documents. Of 660 participants randomized (329 AD109, 331 placebo), 524 (80.0%) completed the study. The registry lists AHI above 5 for eligibility, protocol version 4.0 caps AHI4 at 45, and the baseline abstract states no upper limit. Analysis sets exclude participants from terminated Site 1308. Mean baseline AHI4 was 24, with 37% mild, 33% moderate, and 30% severe.
- Primary endpoint (change in AHI4 at week 26), treatment policy estimand (324 and 326 participants): −3.88 with AD109 and 0.21 with placebo, a difference of −4.08 events/h (95% CI −6.14 to −2.03; p <0.001), or a relative reduction of 33.7% against 7.3%.
- While-on-treatment estimand (240 and 293 participants): −5.83 against −0.02, a difference of −5.81 events/h (95% CI −8.07 to −3.55; p <0.0001), or 46.8% against 6.8% at week 26 and 43.5% against 13.2% at week 51.
- Key secondary endpoints: oxygen desaturation index (3%) relative reduction of 29.5% against 3.5% (treatment policy) and 40.3% against 3.3% (on-treatment); hypoxic burden reduction of 37.4% against 10.0% (treatment policy) and 58.2% against 13.8% (on-treatment); at least 50% AHI reduction in 28.5% against 16.0% (treatment policy; p <0.001) and 38.3% against 15.4% (on-treatment; p <0.0001).
- AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand (on-treatment change −6.5 against −6.9; p = 0.49), and no treatment effect was observed on PROMIS-Sleep Impairment.
- Disease control (AHI below 5) was reported for 22.9% of AD109 participants at week 26 in the on-treatment set. The company attributes the smaller response observed at week 51 to higher treatment discontinuation with AD109 and to control-based imputation of missing data.
Summary: endpoint reordering and FDA questions on clinical meaningfulness
- SynAIRgy: protocol version 4.0 (December 15, 2023) named the proportion of participants with at least 50% reduction in AHI at week 26 as the primary endpoint. Protocol version 6.0, dated 17 April 2025, changed the order of the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry records primary completion on 2025-03-10, so the amendment followed primary completion. Under the amended order, the responder endpoint was tested fifth among the key secondary endpoints (treatment policy P = .182). Statistical analysis plan version 2.0 (22 April 2025) added an exploratory analysis of relative change in AHI4 on the log scale.
- LunAIRo: a protocol amendment made the same reordering with the same stated reason, and a 2025 congress abstract described the primary endpoint as the proportion of participants with at least 50% reduction in AHI4 at six months. The registry records primary completion on 2025-05-07.
- The company states that relative reductions in AHI and hypoxic burden, responder analyses, and shifts to lower severity categories reflect benefit in mild and moderate OSA better than absolute reductions alone, and that its phase 3 analyses used a prespecified proportional (log-scale) model.
- At the pre-NDA meeting, FDA gave feedback on the clinical meaningfulness of certain endpoint results, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. The company states that FDA may determine that the phase 3 clinical response results are not clinically meaningful to establish substantial evidence of effectiveness, or may require additional data, analyses, or studies. The NDA was submitted in April 2026, accepted in July 2026, and has a PDUFA goal date of February 28, 2027.
Summary: pooled phase 3 analyses
The pooled SynAIRgy and LunAIRo analyses included 1,299 randomized participants (648 AD109, 651 placebo), of whom 1,063 (81.8%) completed the trials (Patel et al. 2026b); Patel et al. (2026a) reports 82.3% (1063/1292) of participants who received treatment. Baseline severity was mild in 36.2%, moderate in 37.3%, and severe in 26.5%; the company reports that 51% had AHI below 20 and 74% below 30.
- Treatment policy estimand (626 and 639 participants): AHI4 change of −3.7 against 0.4 events/h, a difference of −4.0 (95% CI −5.6 to −2.5; p <0.0001), or 39.3% against 12.6%; at least 50% AHI4 reduction in 28.3% against 17.7%; hypoxic burden reduction of 41.6% against 9.9%.
- On-treatment estimand (500 and 589 participants): AHI4 difference of −6.2 (95% CI −7.8 to −4.6; p <0.0001), or 51.6% against 13.3%.
- One pooled abstract reports, directly after its on-treatment results and without naming the estimand, at least 50% AHI4 reduction in 39.0% against 18.8%, disease control (AHI4 below 5) in 22.6% against 8.3%, and hypoxic burden reduction of 59.6% against 14.9%; the prospectus labels the pooled 39% responder figure as on-treatment.
- Patient-reported outcomes, on-treatment estimand: differences of −0.48 for PROMIS-Fatigue (P = 0.27), −0.54 for PROMIS-Sleep Impairment (P = 0.26), and −0.18 for the Epworth Sleepiness Scale (P = 0.4). In participants with baseline excessive daytime sleepiness (Epworth score of 10 or more in the treatment policy analysis), PROMIS-Fatigue and PROMIS-Sleep Impairment improved with AD109 (on-treatment P = 0.007 and P = 0.01; treatment policy p = 0.044 and p = 0.048).
- A modeling analysis translated the pooled hypoxic burden reductions into predicted reductions in cardiovascular events or all-cause mortality of 11.9% (treatment policy) and 19.2% (on-treatment); the company states these estimates rest on epidemiologic associations and are not outcomes measured in the trials.
Summary: MARIPOSA and earlier phase 2 studies
- MARIPOSA (NCT05071612) was a phase 2, randomized, double-blind, placebo-controlled, 4-week trial at 25 U.S. sites comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (2:2:3:3) in adults with AHI4 of 10 to 45. Of 211 randomized participants, 181 were in the efficacy analyses, and 29 had baseline AHI4 below 10 after central scoring. The publication tests each AD109 dose against placebo, while the registry primary endpoint compares the combined AD109 arms with placebo; the registry enrollment of 294 includes AD504 arms. Placebo-adjusted AHI4 changes were −7.16 (−11 to −3.3) events/h with 2.5/75 mg and −7.2 (−10.97 to −3.4) with 5/75 mg (P < 0.001 for both), or 47.1% and 42.9%. More than 50% AHI4 reduction occurred in 43.2% and 44.3% against 16.6% with placebo. PROMIS fatigue improved with 2.5/75 mg only (−3.56; P < 0.05), and the authors suggested that 2.5/75 mg may be the optimal dose.
- APC-004, a single-night three-period crossover in mild to moderate OSA (AHI4 of 5 to 20), reported median hypoxic burden of 13.9 (%min)/h on placebo against 2.3 with the high dose and 7.3 with the low dose, and median AHI of 13.2 events/h on placebo against 5.5 and 7.8.
- APC-003 (NCT04580394), a single-dose four-period crossover against each component, reported least-squares mean changes in log10 hypoxic burden of −0.41 for AD109, −0.36 for atomoxetine, −0.04 for R-oxybutynin, and −0.06 for placebo (59 participants per treatment).
- APC-APN-201, an open-label 6-week phase 2 study in 40 participants with OSA and obesity taking AD109 alone (n = 22) or with a GLP-1 receptor agonist (n = 18), reported at least 50% reduction in REI4 on home testing at week 5 in 33.3% and 29.4%, respectively.
Summary: safety and discontinuation across trials
- SynAIRgy safety analysis set (325 AD109, 319 placebo): any treatment-emergent adverse event in 70.8% against 46.7%, treatment-related events in 58.5% against 23.5%, and serious events in 1.5% against 2.5%, all judged unrelated to study medication; no deaths were reported. The most common events with AD109 were dry mouth (35.4% against 9.1%), insomnia (20.6% against 4.7%), nausea (11.4% against 0.6%), and urinary hesitation (8.9% against 0.3%).
- Treatment discontinuation due to adverse events: 21.2% (69/325) with AD109 against 3.1% (10/319) with placebo in SynAIRgy, led by insomnia (4.9%), urinary hesitation (2.5%), and nausea (2.2%); in LunAIRo, 23.7% against 6.6% by month 6 and 28.6% against 10.0% by month 12; pooled, 25.0% (163/653) against 6.7% (43/646) by week 26. Adverse event-related discontinuations occurred predominantly early after treatment initiation.
- Overall treatment discontinuation: in SynAIRgy, 34.3% against 16.3% before week 26 in the publication and 34.6% against 16.5% at month 6 in the main cohort per the prospectus, with 65.7% and 83.7% completing 6 months of treatment; in LunAIRo, 46.5% against 25.1% at month 12; pooled, 35.2% against 15.5% by week 26. Study completion (remaining in the trial) was 83.3% against 85.9% in SynAIRgy and 80.0% overall in LunAIRo.
- LunAIRo: at least one adverse event in 82.9% with AD109 against 68.2% with placebo; dry mouth in 39.63% against 9.48%, middle insomnia in 13.41% against 3.98%, and nausea in 13.11% against 2.14%; serious adverse events in 1.52% against 3.06%, with no deaths. Pooled, at least one treatment-emergent adverse event occurred in 76.6% against 57.3%.
- Insomnia in the phase 3 trials had a median onset of 3 days and a median first-event duration of 16 days, and was mild in 79.2% of cases.
- Cardiovascular measures: in SynAIRgy, heart rate of 100 beats/min or higher on study occurred in 6.3% with AD109 against 1.9% with placebo (P = .006), while systolic blood pressure of 140 mm Hg or higher occurred in 26.3% and 26.5%. LunAIRo 24-hour ambulatory monitoring at week 4 showed changes of 1.9 mmHg in mean arterial pressure and 4.6 bpm in heart rate. No major adverse cardiovascular events were reported with AD109 and five with placebo in the pooled tolerability dataset; the company states the trials were not designed or powered to assess cardiovascular outcomes. People with uncontrolled or resistant hypertension, heart failure, or tachyarrhythmias were excluded from the trials.
- Phase 2: in MARIPOSA, study discontinuation because of adverse events occurred in 12% of each AD109 arm, 19% with atomoxetine alone, and 2% with placebo. In the open-label phase 2 study of AD109 with or without a GLP-1 receptor agonist, treatment-emergent adverse events occurred in 85% of participants, with no deaths or serious events.
- Long-term data: the open-label extension (NCT06566820) registry record, last updated in May 2025, lists an estimated enrollment of 1280; the prospectus states the extension was completed in 2026; the only reported data are a 2025 interim abstract with 102 participants enrolled. An editorial noted that the long-term cognitive safety of chronic antimuscarinic therapy remains uncertain.